ATE145007T1 - Verfahren zur herstellung monoklonaler antikörper mit hilfe eines keimfreien tieres - Google Patents

Verfahren zur herstellung monoklonaler antikörper mit hilfe eines keimfreien tieres

Info

Publication number
ATE145007T1
ATE145007T1 AT89906932T AT89906932T ATE145007T1 AT E145007 T1 ATE145007 T1 AT E145007T1 AT 89906932 T AT89906932 T AT 89906932T AT 89906932 T AT89906932 T AT 89906932T AT E145007 T1 ATE145007 T1 AT E145007T1
Authority
AT
Austria
Prior art keywords
monoclonal antibodies
germs
producing monoclonal
free animal
animal
Prior art date
Application number
AT89906932T
Other languages
English (en)
Inventor
Paul E Gargan
Victoria A Ploplis
Julian R Pleasants
Original Assignee
American Biogenetic Sciences
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Biogenetic Sciences filed Critical American Biogenetic Sciences
Application granted granted Critical
Publication of ATE145007T1 publication Critical patent/ATE145007T1/de

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6815Enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6845Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a cytokine, e.g. growth factors, VEGF, TNF, a lymphokine or an interferon
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531Production of immunochemical test materials
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/745Assays involving non-enzymic blood coagulation factors
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/745Assays involving non-enzymic blood coagulation factors
    • G01N2333/75Fibrin; Fibrinogen
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90Enzymes; Proenzymes
    • G01N2333/914Hydrolases (3)
    • G01N2333/948Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/972Plasminogen activators
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90Enzymes; Proenzymes
    • G01N2333/914Hydrolases (3)
    • G01N2333/948Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/972Plasminogen activators
    • G01N2333/9723Urokinase

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Optics & Photonics (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT89906932T 1988-06-13 1989-06-12 Verfahren zur herstellung monoklonaler antikörper mit hilfe eines keimfreien tieres ATE145007T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US20625988A 1988-06-13 1988-06-13

Publications (1)

Publication Number Publication Date
ATE145007T1 true ATE145007T1 (de) 1996-11-15

Family

ID=22765616

Family Applications (1)

Application Number Title Priority Date Filing Date
AT89906932T ATE145007T1 (de) 1988-06-13 1989-06-12 Verfahren zur herstellung monoklonaler antikörper mit hilfe eines keimfreien tieres

Country Status (6)

Country Link
EP (2) EP0710720A1 (de)
AT (1) ATE145007T1 (de)
AU (1) AU642604B2 (de)
DE (1) DE68927438T2 (de)
SG (1) SG50681A1 (de)
WO (1) WO1989012690A1 (de)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5080883A (en) * 1990-05-11 1992-01-14 Mallinckrodt, Inc. 99 mtcn3s-conjugated anti-bibrin monoclonal antibody as an in vivo diagnostic agent for imaging
US5750652A (en) * 1994-01-21 1998-05-12 Yale University Deltex proteins
US5487892A (en) * 1994-02-24 1996-01-30 American Biogenetic Sciences, Inc. Method for treating thrombotic disease using a fibrin specific monoclonal antibody
US5817768A (en) * 1995-06-07 1998-10-06 The New York Blood Center, Inc. Monospecific antibodies against a subunit of fibrinogen
CN101684155A (zh) 1998-11-06 2010-03-31 苏黎世大学 Nogo基因的核苷酸序列和蛋白序列以及基于其的方法
ES2368419T3 (es) 2000-03-13 2011-11-17 Cornell Research Foundation, Inc. Bloqueo de la migración de leucocitos y de la inflamación por interferencia con cd99/hec2.
US20040033600A1 (en) 2001-03-21 2004-02-19 Palli Subba Reddy Ecdysone receptor-based inducible gene expression system
US7657379B2 (en) 2000-07-05 2010-02-02 Microsoft Corporation Methods and systems for determining the biological function of cell constituents using response profiles
US8105825B2 (en) 2000-10-03 2012-01-31 Intrexon Corporation Multiple inducible gene regulation system
EP1534738B1 (de) 2001-02-20 2012-06-20 Intrexon Corporation Neue substitutionsmutantenrezeptoren und ihre verwendung in einem induzierbaren genexpressionsystem auf grundlage eines nukleären rezeptors
JP4955904B2 (ja) 2001-02-20 2012-06-20 イントレキソン コーポレーション 新規エクジソン受容体/無脊椎動物レチノイドx受容体−ベースの誘導性遺伝子発現システム
WO2002066614A2 (en) 2001-02-20 2002-08-29 Rheogene Holdings, Inc. Chimeric retinoid x receptors and their use in a novel ecdysone receptor-based inducible gene expression system
EP1373470B1 (de) 2001-02-20 2013-04-24 Intrexon Corporation Neue substitutionsmutantenrezeptoren und ihre verwendung in einem induzierbaren genexpressionssystem auf basis eines nukleären rezeptors
US6815175B2 (en) 2001-03-16 2004-11-09 Cornell Research Foundation, Inc. Anti-amyloid peptide antibody based diagnosis and treatment of a neurological disease or disorder
MXPA04002810A (es) 2001-09-26 2005-06-06 Rheogene Holdings Inc Acidos nucleicos receptores de ecdisona de saltarilla, polipeptidos, y sus usos.
US7919269B2 (en) 2001-09-26 2011-04-05 Intrexon Corporation Whitefly ecdysone receptor nucleic acids, polypeptides, and uses thereof
WO2003029422A2 (en) 2001-10-01 2003-04-10 Mount Sinai School Of Medicine Noonan syndrome gene
WO2004014220A2 (en) 2002-08-13 2004-02-19 N-Dia, Inc. Devices and methods for detecting amniotic fluid in vaginal secretions
US7304161B2 (en) 2003-02-10 2007-12-04 Intrexon Corporation Diaclhydrazine ligands for modulating the expression of exogenous genes in mammalian systems via an ecdysone receptor complex
US7456315B2 (en) 2003-02-28 2008-11-25 Intrexon Corporation Bioavailable diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex
US8053232B2 (en) 2004-01-23 2011-11-08 Virxsys Corporation Correction of alpha-1-antitrypsin genetic defects using spliceosome mediated RNA trans splicing
US7935510B2 (en) 2004-04-30 2011-05-03 Intrexon Corporation Mutant receptors and their use in a nuclear receptor-based inducible gene expression system
WO2007005898A2 (en) 2005-07-05 2007-01-11 Cornell Research Foundation, Inc. Blocking leukocyte emigration and inflammation by interfering with cd99l2
WO2007028147A2 (en) 2005-09-01 2007-03-08 Philadelphia Health & Education Corporation D.B.A. Drexel University College Of Medicin Identification of a prostatic intraepithelial neoplasia (pin)-specific gene and protein (pin-1) useful as a diagnostic treatment for prostate cancer
US8093043B2 (en) 2008-06-04 2012-01-10 New York University β-TrCP1, β-TrCP2 and RSK1 or RSK2 inhibitors and methods for sensitizing target cells to apoptosis
US9140692B1 (en) 2010-01-08 2015-09-22 Glycozym, Inc. Methods of identifying glycopeptides recognized by disease-associated auto-antibodies
CA2796942C (en) 2010-04-20 2019-09-24 Cornell University Method for diagnosing melanocytic proliferations
WO2014081633A1 (en) 2012-11-20 2014-05-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Assay to measure midkine or pleiotrophin level for diagnosing a growth
ES2761575T3 (es) 2013-01-02 2020-05-20 Qiagen Sciences Llc Métodos para predecir el tiempo hasta el parto en una mujer embarazada
US9127024B2 (en) 2013-03-15 2015-09-08 Intrexon Corporation Boron-containing diacylhydrazines
AU2015317862A1 (en) 2014-09-17 2017-04-06 Intrexon Corporation Boron-containing diacylhydrazine compounds
WO2017062953A1 (en) 2015-10-10 2017-04-13 Intrexon Corporation Improved therapeutic control of proteolytically sensitive, destabilized forms of interleukin-12
US10656164B2 (en) 2016-12-22 2020-05-19 Qiagen Sciences, Llc Screening asymptomatic pregnant woman for preterm birth
US10935555B2 (en) 2016-12-22 2021-03-02 Qiagen Sciences, Llc Determining candidate for induction of labor
SG11201910113PA (en) 2017-05-02 2019-11-28 Nat Cancer Center Japan Plasmin-cleavable anti-insoluble fibrin antibody-drug conjugate

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4916070A (en) * 1986-04-14 1990-04-10 The General Hospital Corporation Fibrin-specific antibodies and method of screening for the antibodies
AU7912887A (en) * 1986-08-25 1988-03-24 American Biogenetic Sciences, Inc. Monoclonal antibodies to fibrin

Also Published As

Publication number Publication date
DE68927438D1 (de) 1996-12-12
AU642604B2 (en) 1993-10-21
SG50681A1 (en) 1998-07-20
EP0710720A1 (de) 1996-05-08
EP0413763A1 (de) 1991-02-27
AU2097692A (en) 1992-10-22
EP0413763A4 (en) 1991-09-25
WO1989012690A1 (en) 1989-12-28
EP0413763B1 (de) 1996-11-06
DE68927438T2 (de) 1997-03-20

Similar Documents

Publication Publication Date Title
ATE145007T1 (de) Verfahren zur herstellung monoklonaler antikörper mit hilfe eines keimfreien tieres
ATA391682A (de) Verfahren zur herstellung eines monoklonalen antikoerpers gegen tumos-assoziiertes antigen und dessen verwendung
DE3382190D1 (de) Immunogener protein- oder peptidkomplex, verfahren zur herstellung dieses komplexes und seine verwendung als immunstimulans und als impfstoff.
ATE297465T1 (de) Verfahren zur herstellung von multivalenten antigenbindenden proteinen
FI960268L (fi) Menetelmä sairauden diagnosoimiseksi määrittämällä GAGE-tuumorihyljintäantigeenin prekursorien ilmentymistä
CA2103059A1 (en) Method for making humanized antibodies
ATA901983A (de) Verfahren zur herstellung eines monoklonalen antikoerpers
DE3789115D1 (de) Verfahren zur herstellung eines optischen wellenleiters und erzeugnis.
ATA328286A (de) Zell-linien und verfahren zur herstellung von humanen monoklonalen antikörpern sowie kit und verfahren zur bestimmung der anwesenheit von p.aeruginosa
ES548141A0 (es) Un metodo para producir anticuerpos monoclonales especificospara proteina de tensioactivo alveolar de ser humano
DE69331269D1 (de) Verfahren zur herstellung von antikörpern
DE3877558D1 (de) Verfahren zur herstellung polybromierter hoeherer alkylbenzole.
DE3485054D1 (de) Candida albicans zytoplasmaantigen, monoklonale antikoerper dagegen und verfahren zur herstellung.
ATA191890A (de) Verfahren zur herstellung hochfester loetverbindungen
DE3878342D1 (de) Verfahren zur herstellung eines agglomerierten schleifmittels.
ATE73350T1 (de) Verfahren zur tierischen wachstumsfoerderung.
DE69001623D1 (de) Verfahren zur herstellung von fluor-oxy-fluorsulfonylverbindungen durch direkte fluorierung von fluor-beta-sultonen.
DE3861947D1 (de) Verfahren zur herstellung von kurbelwellen.
DE68902702D1 (de) Verfahren zur herstellung von synthetischem schmieroel durch olefinoligomerisation.
DE3880640D1 (de) Verfahren zur herstellung aliphatischer o-arylurethane.
FI973469A0 (fi) Menetelmä tekijän IX valmistamiseksi biologisista lähteistä
DE3869164D1 (de) Zahnaerztliche stange mit diamantbeschichtung sowie verfahren zur herstellung.
AT399885B (de) Verfahren zur herstellung von zellinien, die monoklonale antikörper produzieren
DE58902242D1 (de) Verfahren zur herstellung von thymol.
DE69630039D1 (de) Verfahren zur herstellung gm2-spezifischer antikörper

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee